Compare HCA Health Inc (HCA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Johnson & Johnson — how do they compare? HCA Health Inc trades at $451.09 (market cap $96.35B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 6.4× HCA Health Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Johnson & Johnson for 129 Days on average.
| HCA | JNJ | |
|---|---|---|
Market Cap | $96.35B | $618.09B |
Volume | 1,079,453 | 6,050,983 |
Sector | Health | Health |
52-Week High | $545.13 | $278.43 |
52-Week Low | $361.32 | $186.00 |
Typical Hold Time | 76 Days | 129 Days |
Enterprise Value | $146.88B | $646.37B |
Dividend Yield | 0.7% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $445.01, up 1.33% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.60 billion in 2025, with a net income margin of 8.77%. The stock is supported by a consensus analyst price target of $461.12 and a 63% buy rating. Recent news includes an upcoming Q3 2026 earnings call and completion of the College of Health Care Professions acquisition, highlighting growth initiatives amid ongoing legal investigations.
Outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and regulatory scrutiny. The stock offers value with a P/E of 14.92 and upside to the price target, though high debt levels and legal overhangs warrant caution for investors seeking stable healthcare exposure.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
